ClinicalTrials.gg
Active, not recruitingNCT03294577Updated Jan 15, 2021

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

A Phase 3 interventional study of Pegfilgrastim and Plinabulin in Chemotherapy-induced Neutropenia, sponsored by BeyondSpring Pharmaceuticals Inc.. Active, not recruiting at 20 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by BeyondSpring Pharmaceuticals Inc. · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Neutropenia with a site in Ukraine — 1 open to participants now, 2 under way, 2 of them phase 3. Neutropenia · Ukraine.

Enrollment
4th of 12
221 · median 185
Started
2019
the only one that year
Phase 3
8 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
4 of 12
BeyondSpring Pharmaceuticals Inc.

Among the 12 studies in Neutropenia with a site in Ukraine, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 8 in phase 3, and was the 9th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 12 studies in Neutropenia with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Neutropenia with a site in Ukraine, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with:

Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim

Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L.

Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.

Read the detailed description

This is a multi-center randomized study, double-blind phase 3 trial. Approximately 222 patients are planned to be enrolled in Phase 3.

Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study. These agents are among the most active and commonly used chemotherapeutic agents employed for treating patients with breast carcinoma. In particular, TAC chemotherapy has been used for the adjuvant treatment of HER2 negative early breast cancer patients with node positive disease as well as for node negative breast cancer patients who have a high risk of recurrence.

Plinabulin is a novel small molecule that is being developed for the mitigation of chemotherapy-induced neutropenia. Administered by IV infusion on the same day of (approximately 1 hour after) chemotherapy (TAC), plinabulin will be given in a single dose per cycle. Plinabulin is being studied to see if it is a convenient alternative to G-CSF, pegfilgrastim, for the prevention of chemotherapy-induced neutropenia.

In this trial, treatment will be double blinded, approximately 222 patients with breast cancer are expected to be enrolled. Patients are randomly assigned to one of the treatment arms, with 111 patients enrolled in each arm, with the arm designation and planned intervention as follows:

Arm 1: TAC + pegfilgrastim (6.0 mg) + placebo matching plinabulin.

Arm 2: TAC + pegfilgrastim (6.0 mg) + plinabulin (40 mg).

Cycles 1 to 4 will consist of TAC (or TC for Cycles 2 to 4) administered IV on Day 1 every 21 days. Patients will receive a single dose of plinabulin or placebo IV over 30 minutes (±5 minutes) in a double blinded manner, 30 minutes after the end of the TAC (or TC for Cycles 2 to 4) infusion. On Day 2 of each cycle (≥24 hours after completing chemotherapy), all patients will receive a single dose of pegfilgrastim (6.0 mg).

The long-term safety follow-up through patients contacts by phone calls, letters or electronic means; or medical records reviews will be conducted to all subjects approximately every 6 months up to 5 years to monitor long term safety of plinabulin.

03

Conditions studied

  • Chemotherapy-induced Neutropenia

Browse trials for

Keywords

  • Plinabulin
  • Pegfilgrastim
  • Chemotherapy induced neutropenia
  • bone pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women who are at least 18 years of age at the time of signing the form.
  2. In the opinion of their treating oncology investigator, are candidates for at least 4 cycles of chemotherapy with TAC (docetaxel, doxorubicin, \& cyclophosphamide).
  3. Patients who are candidates for adjuvant or TAC will meet all of the following criteria:

    • -proven, early stage (Stage I and II) and Stage III breast cancer, and
    • Have had no prior chemotherapy.
  4. Pathological confirmation of cancer is required.
  5. (ECOG) performance status of 0 or 1.
  6. Have of 3 months or more.
  7. Laboratory results provided by the central laboratory within 14 days prior to study drug administration within noted ranges, per study protocol (local laboratories may be accepted on a case by case basis after discussion with the medical monitor; however in this case central laboratories must also be taken within the screening time window)
  8. (PT) and International Normalized Ratio (INR) ≤1.5 × , activated partial thromboplastin time (PTT) ≤1.5 × ULN, based on central laboratory results.
  9. Women of have a negative pregnancy test at screening.

Exclusion criteria

Exclusion Criteria:

  1. History of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease.
  2. Use of strong , CYP2D6 or P-glycoprotein (P-gp) inhibitors and inducers, within 14 days of the first administration of study drug and for the duration of the study.
  3. Received an agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no >Grade 1 (CTCAE) (v4.03) treatment emergent adverse events (TEAE).
  4. Receiving any concurrent anticancer therapies (including concomitant anti-/neu agents such as trastuzumab [Herceptin®], trastuzumab emtansine [TDM 1, Kadcyla®], pertuzumab [Perjeta®], lapatinib [Tykerb®]).
  5. Received a prior bone marrow or stem cell transplant.
  6. Have a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug.
  7. Concurrent or prior radiation therapy within 4 weeks before the first dose of study drug.
  8. Chronic use of filgrastim, pegfilgrastim, or any bioequivalent (biosimilar) for severe chronic neutropenia or other chronic neutropenia syndrome.
  9. Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, and psychiatric illness that would limit compliance with study requirements or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator.
  10. Significant cardiovascular history:

    • Cardiac ventricular dysfunction inhibiting the patient's ability to receive 4 cycles of doxorubicin.
    • History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration
    • Uncontrolled arrhythmia
    • History of congenital
    • (ECG) findings consistent with active ischemic heart disease
    • Class III or IV cardiac disease;
    • Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic in spite of antihypertensive medication
  11. History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
  12. Any other active requiring active therapy.
  13. Known (HIV) seropositivity.
  14. Active virus (HBV) infection which requires antiviral treatment or the patient has detectable Hepatitis B surface Antigen (HBsAg); hepatitis B surface antibody (anti-HBs) without detectable HBsAg does not exclude patients from the study. infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study.
  15. Female patient who is pregnant or lactating.
  16. Use of prophylactic antibiotics.
  17. Unwilling or unable to comply with procedures required in this protocol.
  18. History of allergy to any of the study drugs.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
221 participants (actual)

Study arms

  • Active comparator
    TAC + Pegfilgrastim

    Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

    Drug: Pegfilgrastim · Other: D5W Placebo · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Pegfilgrastim + Plinabulin

    Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)

    Drug: Plinabulin · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

Interventions

  • PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

    Also known as: Neulasta, G-CSF

  • Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

    Also known as: BPI-2358, NPI-2358

  • OtherD5W Placebo

    Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

  • DrugDocetaxel, doxorubicin, and cyclophosphamide (TAC)

    Drug page: Docetaxel

    Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

    Also known as: Taxotere, Adriamycin, Cytoxan

06

What researchers measure

Primary outcomes

  1. Percentage of patients with Duration of Severe Neutropenia (DSN) =0

    DSN is defined as Days of Grade 4 Neutropenia (ANC less than 0.5 X 109/L)

    Time frame: Duration of Grade 4 neutropenia assessed during the first cycle (21 days)

Secondary outcomes

  1. Mean DSN assessment

    DSN is defined as Days of Grade 4 Neutropenia (ANC less than 0.5 X 109/L)

    Time frame: From day 1 to day 8 in first cycle (21 days)

  2. Mean ANC nadir

    record and evaluate the lowest ANC value

    Time frame: Duration of first cycle (21 days)

  3. Percentage of Patients without grade 3 and grade 4 neutropenia

    ANC less than 1 x 109/L and above 0.5x 109/L is defined as grade 3 neutropenia. ANC less than 0.5 X 109/L is defined as grade 4 neutropenia.

    Time frame: Duration of first cycle (21 days)

  4. Mean DSN assessment within 15 days

    To evaluate the effect of Plinabulin related to DSN within 15 days

    Time frame: From day 1 to day 15 in the first cycle (21 days)

  5. Average change in bone pain

    Record the bone pain score from the numerical rating scale (NRS)

    Time frame: From -1 day over the observational period

  6. Rate of composite risks

    Composite risks includes infection, FN, hospitalization, significant disability, life threatening and death

    Time frame: Duration of all 4 cycle (21 days)

  7. Percentage of patients with relative dose intensity < 85%

    Assess the percentage of patients with RDI \< 85%

    Time frame: Duration of all 4 cycle (21 days)

07

Study locations

20 sites
  • No. 1 Banshandong Road
    Hangzhou, Gongshu District, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Cancer Center of Guangzhou Medical University Breast Oncology
    Guangzhou, Guangzhou 510000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Harbin 150000, China
  • Fourth Hospital of Hebei Medical University Breast cancer department
    Shijiazhuang, Hebei 500000, China
  • China-Japan Union Hospital of Jilin University Tumor department of Hematology
    Changchun, Jilin 130000, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Shenyang 110000, China
  • Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department
    Dnepropetrovsk, 49102, Ukraine
  • Prykarpatskiy Regional Oncological Center
    Ivano-Frankivs'k, Ukraine
  • Regional Clinical Oncology Center
    Kharkiv, Ukraine
  • V.T. Zaycev Institute
    Kharkiv, Ukraine
  • Public Institution Kryvyi Rih Oncology Center
    Krivoy Bereg, 50048, Ukraine
  • Kirovograd Regional Oncological Center
    Kropyvnytskyi, 25011, Ukraine
  • Hemotherapy Department
    Kyiv, Ukraine
  • Kyiv City Clinical Oncological Center
    Kyiv, Ukraine
  • Lviv State Oncological Regional
    Lviv, Ukraine
  • Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho
    Odessa, 65025, Ukraine
  • Zakarpattia Regional Clinical Oncology Center
    Uzhgorod, Ukraine
  • Vinnytsya Regional Clinical Oncology Dispensary
    Vinnytsia, Ukraine
  • Zaporizhia Regional Clinical Oncology Dispensary
    Zaporizhzhya, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2020, 11 months.

Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2017
First posted
Sep 27, 2017
StartActual
Oct 23, 2019
Primary completionActual
Sep 25, 2020
CompletionEst.
Sep 25, 2025
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03294577
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Oct 23, 2019
Primary completion
Sep 25, 2020
Completion
Sep 25, 2025 (estimated)
Last update
Jan 15, 2021

Study contacts

Douglas Blayney, M.D.
study chair · Stanford University School of Medicine - Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NPI 2358

Start the discussion